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Abstract
Tuberculosis (TB) remains a major global public health problem. The only vaccine, BCG, gives variable protection, especially
in adults, so several new vaccines are in clinical trials. There are no correlates of protective immunity to TB; therefore
vaccines progress through lengthy and expensive pre-clinical assessments and human trials. Correlates of protection could
act as early end-points during clinical trials, accelerating vaccine development and reducing costs. A genome-wide
microarray was utilised to identify potential correlates of protection and biomarkers of disease induced post-BCG
vaccination and post-Mycobacterium tuberculosis challenge in PPD-stimulated peripheral blood mononuclear cells from
cynomolgus macaques where the outcome of infection was known. Gene expression post BCG-vaccination and post
challenge was compared with gene expression when the animals were naı¨ve. Differentially expressed genes were identified
using a moderated T test with Benjamini Hochberg multiple testing correction. After BCG vaccination and six weeks post-M.
tuberculosis challenge, up-regulation of genes related to a Th1 and Th17 response was observed in disease controllers. At
post-mortem, RT-PCR revealed an up-regulation of iron regulatory genes in animals that developed TB and down-regulation
of these genes in disease controllers, indicating the ability to successfully withhold iron may be important in the control of
TB disease. The induction of a balanced Th1 and Th17 response, together with expression of effector cytokines, such as
IFNG, IL2, IL17, IL21 and IL22, could be used as correlates of a protective host response.
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Introduction
Tuberculosis (TB) is still a major global public health issue [1].
The exact mechanisms of protection induced by the only vaccine
currently licensed, BCG, have not been fully elucidated and the
development of new interventions has been hindered by the lack of
a definitive correlate of protection. Therefore, potential TB
vaccine candidates have to be tested empirically for ‘‘protection’’
in a range of animal models, from which the more promising
vaccines are selected for progression into lengthy and expensive
clinical trials, often involving numerous at-risk individuals in
endemic countries. The identification of correlates of protection
for TB would prove beneficial in the development of a new
vaccine in several ways. A validated correlate of protection could
be used in screening new vaccine candidates to ascertain that they
generate an appropriate immune response and also be used as a
surrogate end-point during clinical trials, substituting for a clinical
end-point. This would accelerate clinical trials and vaccine
evaluation in pre-clinical studies, which would not only reduce
costs but also allow the assessment of a greater number of vaccine
candidates in a set period of time. Much time, money and research
has gone into trying to clarify the interactions that occur between
pathogen and host, and through this analysis, it has become
evident that the immune response to Mycobacterium tuberculosis is a
complex and multifaceted process. Studies have shown the
importance of the Th1 immune response and cytokines, such as
interferon gamma (IFNG), interleukin (IL)-12 and tumor necrosis
factor (TNF) in the control of TB disease [2–4]. IFNG, in
particular, is essential for protective immunity to tuberculosis, and
individuals who carried a genetic deficiency in the receptor for
IFNG were more likely to succumb to mycobacterial infection
[2,5]. IFNG was once proposed as a potential correlate of
protection, but it is now apparent that IFNG alone is not a reliable
correlate as its production before and during a mycobacterial
infection is not predictive of protection against disease [6–8] and it
is likely that other factors, possibly ones that are regulated by the
cytokine, may be involved [9]. Other aspects of the immune
response proposed to play a role in protection against TB include
CD8+ T cells, Th17 cells, cd T cells, CD1-restricted invariant
Natural Killer T (iNKT) cells and mucosal-associated invariant T
(MAIT) cells [10–14]. Several methods have been employed to
assess responses induced by vaccination and challenge. ELISAs
and LuminexH technology are used to detect cytokines including
IFNG, the ELISPOT is used to determine the frequency of
antigen-specific T cells, and flow cytometry can be used to assess
cell surface markers and intracellular cytokines. However,
resources are often limited so not all of these technologies can
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be applied. Choices need to be made; therefore bias is introduced
into the analysis. A whole-genome approach may be a more
realistic method by which to identify correlates of protection as
aspects of all areas of the immune system can be examined
together, along with other facets of the response which might
currently be considered unrelated, or unimportant. Transcrip-
tomics provides a way to do this and has been used to identify
genes associated with BCG-vaccination success in mice [15].
As our closest relatives phylogenetically, non-human primates
(NHPs) have been utilised to model tuberculosis infection because
they are naturally susceptible to M. tuberculosis, share clinical and
pathological changes caused by TB in humans, and are also
protected to varying degrees by BCG vaccination. The NHP
model has been used to evaluate vaccine-induced immunity to
tuberculosis [16–19]. Data derived from studies in NHPs are
believed to hold strong predictive validity and support the
development of the more promising vaccine candidates. An
advantage of the NHP model is that sequential samples can be
taken, providing the opportunity for longitudinal analyses, which is
not feasible in smaller animal models. In addition, other factors,
such as infective dose and time from infection can be controlled,
which is not possible in human studies. Therefore, the NHP model
provides a definable experimental approach to identifying
biomarkers.
In this study, microarray technology has enabled a genome-
wide examination of gene expression in response to BCG-
vaccination and TB infection by utilising an archive of peripheral
blood mononuclear cells (PBMCs) isolated and cryopreserved
during a vaccine efficacy study in NHPs where the outcome of
infection was known. Due to the number of animals involved in
the original study, the aim of this analysis was to generate biology-
driven hypotheses from the molecular data, and fresh insights with
which to inform future studies, rather than identifying a distinctive
biosignature of protection or disease as has been carried out in
other studies [45]. Deciphering mechanisms of host-mediated
immune responses to this highly adapted intracellular pathogen in
the cynomolgus macaque model of TB, by identifying responses
indicative of protection or disease progression, could potentially
provide an important step forward for developing and evaluating
new interventions.
Methods
Ethics Statement
Animals were housed according to the Home Office (UK) Code
of Practice for the Housing and Care of Animals Used in Scientific
Procedures (1989) and the National Committee for Refinement,
Reduction and Replacement (NC3Rs) Guidelines on Primate
Accommodation, Care and Use, August 2006, for the care and
maintenance of primates. All protocols involving animals were
approved by the Ethical Review Committee of the Public Health
England, Porton, UK. Following local ethical review, project
licence 30/2565 was subsequently granted by the UK Home
Office.
Experimental Animals
Twelve male captive-bred cynomolgus macaques of Chinese
origin were used for this study. CITES permit and Home Office
approval were obtained prior to importation. Animals were
housed in social same-sex groups of 4 to 6 in cages that met with
the UK Home Office Code of Practice and the European
Standard ETS123. Animals were given ad libitum access to sterile
bottled water and primate expanded mazuri pellets (SQC). This
was supplemented by forage mix, fresh fruit and vegetables at
regular intervals. Environmental enrichment was provided by a
varied programme that included toys, puzzle feeders and DVDs
for visual stimulation. All animals underwent full veterinary health
inspection on arrival and there were subsequent daily checks on
clinical signs and behaviour. At 2 week intervals each animal was
examined under sedation, weighed and a blood sample was taken
for immunological and health screening.
All animals were 4 years old at the time of challenge, weighing
between 2.8–4.4 Kg, and naı¨ve in terms of prior exposure to
mycobacterial antigens (M. tuberculosis infection or environmental
mycobacteria) as demonstrated by the tuberculin test whilst in
their original breeding colony and by the IFNG based Primagam
test kit (Biocor, CSL, USA) just prior to study start. Monkeys were
sedated by intramuscular (i.m.) injection with ketamine hydro-
chloride (10 mg/kg) (Ketaset, Fort Dodge Animal Health Ltd,
Southampton, UK) for all procedures requiring removal from
their cages. None of the animals had been used previously for
experimental procedures. The time of necropsy if prior to the end
of the planned study period was determined by experienced
primatology staff based on a combination of the following adverse
indicators: depressed or withdrawn behaviour, dyspnoea, loss of
20% of peak post-challenge weight, erythrocyte sedimentary rate
(ESR) levels elevated above normal, haemoglobin level below
normal limits, increased temperature and severely abnormal chest
X-ray. At termination animals were anaesthetised with ketamine
at 0.2 ml/Kg and then killed with an overdose of pentobarbitone
sodium.
BCG-Vaccination
A plan of the vaccination strategy and timing of the aerosol
challenge is shown in Figure 1. Six of the twelve Chinese
cynomolgus macaques were immunised intradermally in the upper
left arm with 100 ml BCG, Danish strain 1331 (SSI, Copenhagen,
Denmark). The BCG vaccine was prepared and administered
according to manufacturer’s instructions for preparation of
vaccine for administration to human adults, by addition of 1 ml
Sauntons diluent to a vial of vaccine, to give a suspension of BCG
at an estimated concentration of 26106 to 86106 CFU/ml.
M. tuberculosis Challenge
Twenty-one weeks after immunisation with BCG, the six BCG-
immunised animals together with six unvaccinated animals were
challenged by the aerosol route with M. tuberculosis Erdman strain
K 01, kindly provided by Dr Amy Yang (CBER/FDA now BEI
Resources), (Figure 1) as previously described [20]. The process to
deliver a known number of viable M. tuberculosis bacilli in a target
volume of inspired aerosol was performed. Challenge was
performed on sedated animals placed within a ‘‘head-out’’
plethysmography chamber (Buxco, Wilmington, NC) to enable
the aerosol to be delivered simultaneously with the measurement
of the respiration rate. Animals received an aerosol dose of 75
CFU and were monitored for a maximum of 28 weeks post
infection (p.i.).
Isolation and Stimulation of PBMCs
Peripheral blood mononuclear cells (PBMC) were isolated from
heparin-anticoagulated blood by Ficoll-Hypaque Plus (GE
Healthcare, Buckinghamshire, UK) density gradient separation
using standard procedures. PBMCs were isolated from two time-
points when the animals were naı¨ve, at 8 weeks post-vaccination in
animals that received BCG, and at 6 weeks post-M. tuberculosis
challenge in all animals and cryopreserved in 10% DMSO/90%
foetal bovine serum, on day of isolation. Time-points were selected
based on immunological responses observed in ELISPOT, IFNG
Host Response to BCG Vaccination and TB Challenge
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ELISA and whole blood intracellular staining gathered during the
vaccine efficacy study (data not shown) where peak responses to
BCG vaccination were observed around 8 weeks post-vaccination.
Six weeks post-challenge was selected as it allowed time for an
adaptive immune response to be mounted but before inflamma-
tion or infection could overwhelm the gene expression signal.
Later, PBMCs were thawed, washed and resuspended in medium
consisting of RPMI 1640 supplemented with L-glutamine (2 mM),
penicillin (50 U/ml)/streptomycin (50 mg/ml) and 10% heat-
inactivated foetal bovine serum with 50 U/ml Benzonase (Scien-
tific Laboratory Supplies Ltd, Nottingham, UK ), pre-warmed to
37uC and ‘‘rested’’ for 2 hours at 37uC in 5% CO2. After resting,
cells were washed and cell concentrations adjusted to 26106 cells/
ml in medium. PBMCs were stimulated with 30 mg/ml purified
protein derivative (PPD) (SSI, Copenhagen, Denmark) for 16
hours at 37uC in the presence of 5% CO2.
RNA Isolation and Purification
RNA was isolated from PBMC samples using Trizol reagent
(Invitrogen, Paisley, UK) as described in the manufacturer’s
protocol, and RNA purified using RNeasy spin columns (Qiagen,
Crawley, UK) including an on-column DNA digest step (Qiagen,
Crawley, UK). RNA was quantified using a NanoDrop ND1000
UV-vis spectrophotometer (NanoDrop Technologies, Cambridge,
UK), and the quality assessed using the Agilent 2100 Bioanalyzer
(Agilent Technologies, Stockport, UK). All RNA samples used for
microarray and real-time PCR (RT-PCR) analysis had an RNA
Integrity Number (RIN) of at least 7.0.
Microarray Procedure
50 ng of RNA extracted from PPD-stimulated PBMCs was used
for microarray analysis. RNA was amplified and labelled using the
Agilent Low Input Quick Amplification Labelling kit (Agilent
Technologies, Stockport, UK) with RNA spike-ins (Agilent
Technologies, Stockport, UK), as per kit instructions. cRNA was
purified using the Qiagen RNeasy mini columns (Qiagen,
Crawley, UK) and the yields and dye-incorporation rate were
measured using a NanoDrop ND1000 UV-vis spectrophotometer.
The hybridization procedure was performed according to the
Agilent 60-mer oligo microarray processing protocol using the
Agilent Gene Expression Hybridization Kit. Briefly, 1.65 mg Cy3-
labelled fragmented cRNA in hybridization buffer was hybridized
overnight (17 hours, 65uC, 10 rpm) to Agilent Rhesus Macaque
Gene Expression Microarrays 4644 K (Array ID-15421) using
Agilent’s recommended hybridization chamber and oven. Slides
were washed and scanned using the Agilent’s High-Resolution C
Scanner at a resolution of 5 mm. Data were extracted using Agilent
Feature Extraction software v10.7 using the default settings for 1-
colour gene expression analysis (protocol GE1_107_Sep09), which
determines feature intensities, subtracts background signal, rejects
outliers and calculates statistical confidences. Complete micro-
array data are available at the Gene Expression Omnibus (GEO)
database under the accession number GSE42273.
Data Analysis
Initial data analysis was carried out using GeneSpring GX12
(Agilent Technologies, Stockport, UK). Data underwent quantile
normalisation and the expression profiles post-vaccination and
post-challenge were baseline transformed to expression at the
naı¨ve time-points for each animal. Samples were grouped
according to immune status (naı¨ve, post-vaccination, post-
challenge), vaccination status (vaccinated, unvaccinated) and
whether the animal was able to control infection for the duration
of the study or not (controllers, progressors). Gene expression post-
vaccination and post-challenge was compared to gene expression
at the naı¨ve time-points for each group in pair-wise comparisons.
Genes were filtered according to expression and fold-change so
that only genes which were detected in at least 50% samples in 1 of
the 2 conditions i.e. naı¨ve or post-vaccination/post-challenge and
had a fold change of at least 1.75 at post-vaccination and 2.00 at
post-challenge, were used for further analysis. A moderated T-test
with Benjamini-Hochberg false discovery rate (FDR) correction
for multiple testing was performed to identify differentially
expressed genes with a corrected p-value threshold of 0.05 for
the post-vaccination time-point and 0.01 for the post-challenge
time-point. The more stringent limits were used for the post-
challenge time-point as a greater number of genes were found to
be differentially expressed so analysis was focused on the most
significant genes exhibiting greatest fold changes in expression
(fold change .2, corrected p-value ,0.01).
Real-time PCR
A subset of genes was selected for further investigation and for
validation of expression by RT-PCR. The High Capacity RNA-
to-cDNA kit (Applied Biosystems, Warrington, UK) was used to
reverse transcribe RNA extracted from PBMCs as per kit
Figure 1. Vaccination and challenge schedule. Twelve Chinese cynomolgus macaques were involved in the study. Six animals received BCG-
vaccination and six animals remained unvaccinated prior to aerosol challenge with M. tuberculosis. All animals were followed for a maximum of 28
weeks post-infection. Time-points at which gene expression analysis was carried out are shown in bold. PM = post-mortem.
doi:10.1371/journal.pone.0088149.g001
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instructions and cDNA was stored at 220uC until use. Pre-
designed and pre-optimized TaqmanH gene expression assays and
TaqManH Gene Expression Master Mix were used with the
Applied Biosystems 7900HT Real-Time PCR system. All assays
were designed to span exon boundaries. Assay ID were
Rh02847367 (B2M), Rh02842097_m1 (CXCL9),
Rh02789784_m1 (FTH1), Rh02621747_m1 (HMOX1),
Rh02788577_m1 (IFNG), Rh02789780_m1 (IL2),
Rh02789322_m1 (IL6), Rh02621748_m1 (IL12B),
Rh02621750_m1 (IL17), Rh02879198_m1 (IL21),
Rh02877345_m1 (IL22), Rh02872166_m1 (IL23A),
Rh02796598_m1 (SLC11A1), Rh02829242_m1 (SLC11A2),
Rh02621758_m1 (TFRC), Rh02789784_m1 (TNF). Reactions
were run in triplicate and the fold increase was calculated using the
relative quantification method, with B2M used as the endogenous
control and the PPD-stimulated naı¨ve samples for each animal
used as the calibrator sample. All RT-PCR data were analysed
using the ABI SDS 2.4 and RQ manager 1.2.1 software.
Significant differences between expression profiles were deter-
mined by Student T tests carried out on the log2-transformed RT-
PCR data; a p-value of ,0.05 was taken as statistically significant
using SigmaPlot 11.0.
Role of Iron Homeostasis in TB Disease
Microarray data highlighted a potential role of iron homeostasis
in the control of TB disease. This was investigated further by
analysing the expression of five genes involved in the control of
cellular iron in unstimulated PBMCs isolated from the six
unvaccinated cynomolgus macaques at post-mortem, using RT-
PCR. At the point of necropsy, the animals had either succumbed
to infection and TB disease had progressed to reach humane end-
point criteria, or had managed to control the infection showing
little or no overt symptoms of disease.
Results
Outcome of Challenge and Grouping of Animals
All twelve animals involved in the vaccine efficacy study were
challenged by the aerosol route with M. tuberculosis. The six animals
that received BCG prior to challenge all controlled the infection
for the duration of the study (28 weeks post-challenge). This group
is referred to as ‘‘vaccinated controllers’’. Three of the unvacci-
nated animals were also able to control infection for the duration
of the study and are referred to as ‘‘unvaccinated controllers’’. The
remaining three unvaccinated animals developed active TB
disease and reached humane end-point criteria before the end of
the study and are referred to as ‘‘unvaccinated progressors’’.
Differentially Expressed Genes Identified Following BCG-
Vaccination
Using a fold change cut off of at least 1.75 and a corrected p-
value cut off of 0.05, a list of 13 genes were found to be
significantly differentially expressed 8 weeks after BCG-vaccina-
tion in the 6 animals that received BCG (Table 1). The gene
exhibiting the greatest increase in expression was the cytokine
CXCL9. Also within the list were the genes expressing the closely
related chemokines CXCL10 and CXCL11 and the Th1-associated
cytokines, IL2 and IFNG. In addition, the pro-inflammatory
cytokine IL17 was significantly up-regulated with a fold change of
2 from the naı¨ve time-point.
Differentially Expressed Genes Identified Following M.
tuberculosis Challenge
The cynomolgus macaques were defined as either vaccinated
controllers, unvaccinated controllers or unvaccinated progressors
depending on their vaccination status at the time of challenge and
whether they controlled disease for the duration of the study (28
weeks after aerosol challenge) or whether TB disease progressed
sufficiently to meet humane end-point criteria.
Transcriptomic analysis of PPD-stimulated PBMCs isolated six
weeks post-infection from the six vaccinated controllers revealed
705 transcripts representing 662 genes, which were significantly
differentially expressed from naı¨ve time-points using a corrected p-
value of ,0.01. Of these transcripts, 341 were significantly up-
regulated and 364 were significantly down-regulated (Table S1).
Three cynomolgus macaques that were not vaccinated prior to
challenge with M. tuberculosis were able to control the infection for
the duration of the study. For this experimental group, 2706
transcripts, representing 2559 genes, were differentially expressed
in comparison to the naı¨ve time-point; 1233 were up-regulated
and 1473 were down-regulated (Table S2).
Three cynomolgus macaques that did not receive a BCG
vaccination before challenge with M. tuberculosis developed TB
disease that met humane end-point criteria before the end of the
study. In this group of animals, 1958 transcripts, representing 1828
genes, were differentially expressed in PPD-stimulated PBMCs
isolated at six weeks post-challenge. Of these transcripts, 963 were
up-regulated and 995 were down-regulated from the naı¨ve time-
points (Table S3).
The gene lists generated from pair-wise comparisons of
expression post-challenge were compared across experimental
groups to determine which genes were shared and which were
expressed solely by either the controllers or progressors in order to
identify those which potentially correlated with protection or were
biomarkers of disease (Figure 2).
Differentially Expressed Genes Common to All
Experimental Groups
Comparing the gene lists from each of the experimental groups
revealed a common list of 325 genes which were differentially
expressed in all groups six weeks after challenge (Figure 2); 156
genes were up-regulated and 169 down-regulated from the naı¨ve
time-point. Up-regulated genes included the chemokines and
cytokines CSF2, CSF3, CXCL10, IL12B, IL1F9, IL23A, TNF and
TNFAIP6 and cell surface proteins macrophage scavenger receptor
(MSR)-1, CD274 and intercellular adhesion molecule (ICAM)-1.
Also up-regulated across all groups were the genes expressing the
enzymes prostaglandin E synthase (PTGES) and prostaglandin-
endoperoxide synthase 2 (PTGS2), which are involved in the
biosynthesis of prostaglandin E2 (PGE2) and showed the greatest
increase in the animals that developed TB disease.
Of the 156 genes up-regulated across all groups, the unvacci-
nated progressors had 25 genes with a fold change greater than 10
compared to just 2 and 3 genes with a fold change greater than 10
for the vaccinated and unvaccinated controllers, respectively. The
greatest difference was seen for the high affinity immunoglobulin
gamma Fc receptor I (FCGR1), typically expressed on monocytes,
which was increased 29 fold in the disease progressors but just 3–4
fold in the vaccinated and unvaccinated disease controllers.
Differentially Expressed Genes in Vaccinated Cynomolgus
Macaques able to Control TB Infection Only
101 transcripts were found to be differentially expressed in the
cynomolgus macaques that received BCG vaccination and were
Host Response to BCG Vaccination and TB Challenge
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able to control infection following M. tuberculosis challenge, which
were not differentially expressed in any of the other experimental
groups (Figure 2); 52 were up-regulated from the expression levels
obtained when the animals were naı¨ve and 49 were down-
regulated. The gene exhibiting the greatest fold increase in
expression was oncostatin M (OSM), which codes for a cytokine
belonging to the same family of IL6, which exhibited a 6.5 fold
increase from the naı¨ve time-point. Also amongst the up-regulated
genes were the Th17 lineage-specific transcription factor, RAR-
related orphan receptor (ROR)-C, serpin peptidase inhibitor,
clade G (C1 inhibitor) member 1 (SERPING1), an inhibitor of the
complement cascade, selectin E (SELE) which mediates the
adhesion of cells to the vascular lining and accumulation of
leukocytes at sites of inflammation, the cytokines IL10 and IL26
and cytokine receptor IL15RA, and suppressor of cytokine
signalling (SOCS) - 2. Among the down regulated genes was the
Fc receptor-like 2 (FURL), which plays a negative immunomod-
ulatory function in the regulation of memory B cells.
Table 1. Differentially expressed genes in PPD-stimulated PBMCs isolated from cynomolgus vaccinated controllers 8 weeks post-
BCG vaccination.
Agilent Probe ID Gene Symbol Gene Name Fold change
Corrected
p-value
A_01_P019234 CXCL9 chemokine (C-X-C motif) ligand 9 10.451 1.2 E-04
A_01_P005324 CXCL11 chemokine (C-X-C motif) ligand 11 3.939 2.6 E-04
A_01_P017394 IL2 interleukin 2 3.647 4.1 E-04
A_01_P016296 CXCL10 chemokine (C-X-C motif) ligand 10 2.402 3.2 E-03
A_01_P011873 IL17 interleukin 17A 2.153 1.7 E-02
A_01_P013686 SERPING1 serpin peptidase inhibitor, clade G 1 2.040 9.6 E-03
A_01_P000478 IFNG interferon-gamma 1.988 6.0 E-03
A_01_P015977 APOL6 apolipoprotein L6-like 1.973 1.1 E-02
A_01_P012338 CCL20 chemokine (C-C motif) ligand 20 1.922 9.6 E-03
A_01_P013340 LOC100430310 hypothetical protein 1.873 6.0 E-03
A_01_P019222 KLF16 insulinoma-associated protein 1-like 1.787 4.1 E-02
A_01_P002902 NLGN4X neuroligin 4 1.751 6.0 E-03
A_01_P009015 CLEC1A C-type lectin domain family 1, member A –1.800.8 6.0 E-03
Fold change indicates the change in gene expression in PPD-stimulated PBMCs isolated at 8 weeks post-BCG vaccination compared with PPD-stimulated PBMCs isolated
pre-vaccination when the animals were naı¨ve (n = 6).
doi:10.1371/journal.pone.0088149.t001
Figure 2. Comparison of differentially expressed gene lists across experimental groups. Microarray analysis was used to identify
differentially expressed genes in PPD-stimulated PBMCs isolated at 6 weeks post-challenge with M. tuberculosis from vaccinated controllers (n = 6),
unvaccinated controllers (n = 3) and unvaccinated progressors (n = 3) compared with expression when animals were naı¨ve. Key genes of interest in
each list are indicated. Underlined genes were down-regulated in expression from naı¨ve time-points.
doi:10.1371/journal.pone.0088149.g002
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Differentially Expressed Genes in Both Cynomolgus
Vaccinated and Unvaccinated Controllers of Disease Only
163 genes were differentially expressed in animals that were able
to control infection, regardless of their vaccination status (Figure 2);
46 were up-regulated from the naı¨ve time-point and 117 down-
regulated. Amongst the most up-regulated genes were the
chemokines CXCL9 and CXCL11, which were also amongst the
most up-regulated genes after vaccination in the BCG-immunised
animals. Similarly, IL2 and IFNG were significantly up-regulated
in both vaccinated and unvaccinated controllers post-challenge, as
was IL17. In addition, a number of other Th17-related immune
genes were differentially expressed in animals able to control TB
infection including the effector cytokines, IL21 and IL22, and the
transcription factor, RORA. Amongst the down-regulated genes
were phospholipase C gamma 2 (PLCG2) involved in T cell
receptor signal transduction and the toll-like receptors (TLR)-7,
TLR9 and TLR10 which exhibited fold changes of -3, -2 and -3,
respectively, from the naı¨ve time-point.
Differentially Expressed Genes in Cynomolgus
Unvaccinated Disease Progressors Only
Of the 1958 genes which were differentially expressed in the
cynomolgus macaques that were unvaccinated and succumbed to
disease following challenge with M. tuberculosis, 894 were differen-
tially expressed by this group of animals and not in either group of
animals that were able to control infection (Figure 2); 548 were up-
regulated from the naı¨ve time-point and 346 were down-regulated.
Among the up-regulated genes were PTGS1, CCL23, CD14,
TLR2, TLR4 and TLR8, the interferon associated genes IFNB1,
IFI44L and IFIT2 and also 12-LO and FPR2 which are involved in
lipoxin signalling. In addition, within this gene list were a number
of genes associated with iron homeostasis including ferritin heavy
chain (FTH1), SLC11A1, transferrin receptor (TFRC), heme
oxygenase 1 (HMOX1) and 5-aminolevulinate synthase, ery-
throid-specific, mitochondrial (ALAS2) which all exhibited up-
regulation from the naı¨ve time-point. Down-regulated genes
include TLR3, IFNA13 and IFNA14.
Iron Regulation in TB Disease
Microarray analysis revealed an up-regulation of a number of
iron-regulatory genes in PPD-stimulated PBMCs isolated six weeks
post-challenge from animals that were unable to control TB
infection, which were not significantly differentially expressed in
animals that controlled disease. To further investigate the role of
iron homeostasis in tuberculosis disease, RT-PCR was used to
determine the expression of five genes involved in iron homeostasis
in unstimulated PBMCs isolated at post-mortem in the six
unvaccinated cynomolgus macaques at which point three animals
had succumbed to infection and three had successfully managed to
control infection for the duration of the study (28 weeks p.i).
RT-PCR analysis revealed up-regulation of all of the iron
regulatory genes (FTH1, SLC11A1, SLC11A2, TFRC and HMOX1)
in disease progressors and a down-regulation of the same genes in
disease controllers in PBMCs isolated at post-mortem, with
statistically significant differences between the two groups for all
5 genes (Figure 3).
RT-PCR Validation of Microarray Data
To validate the microarray data, RT-PCR was used to
determine the fold change in expression of six genes post-
vaccination and/or post-challenge for all experimental groups,
compared to expression at the naı¨ve time-point. Student T tests
were carried out on log2-transformed RT-PCR expression data to
determine whether the genes were differentially expressed from
the naı¨ve time-point, with a p value ,0.05 considered statistically
significant. Expression profiles generated from the two techniques
are shown in Figure 4. Time-points at which the genes were
determined as differentially expressed are indicated on the plots.
There was agreement for 100% of comparisons providing
confidence in the microarray data obtained.
Discussion
BCG is the only licensed vaccine for tuberculosis but offers
variable protection, particularly against pulmonary tuberculosis,
which is the most common form of the infection in adults;
therefore, the development of a more effective vaccine is critical
for the control of the on-going TB pandemic [21]. The
identification of a definitive correlate of protection for TB would
accelerate the process of clinical trials and pre-clinical assessments
by acting as a surrogate end-point. Similarly, identification of
biomarkers of TB disease could speed up the assessment of new
anti-tuberculosis drugs and therapies [22].
Vaccine efficacy in TB NHP models, as with other in vivo
models, is typically measured either as an increase in survival
period following challenge, or as a reduction in TB-induced
disease burden measured by changes in clinical parameters (such
as weight loss, temperature increase, increase in markers of
inflammation e.g. erythrocyte sedimentation rate (ESR), and
decrease in red cell haemoglobin); organ-specific bacterial burden;
or the number and extent of lesions in pulmonary and extra-
pulmonary tissues measured using a qualitative gross pathology
scoring system. The study report here was designed to use the
comparative measures of disease burden (described above) applied
28 weeks after challenge, to evaluate the effect of BCG
vaccination. The disease burden measured in the BCG vaccinated
animals was significantly lower than that measured in the
unvaccinated group (weight loss p = 0.0163; RBC haemoglobin
p = 0.0051; ESR p = 0.0135; Total pathology score p = 0.0131)
and therefore supports the conclusion that BCG vaccination leads
to an improved outcome. The difference in rate of TB disease
development between the BCG vaccinated and unvaccinated
groups is reflected by ‘survival’, and approaches significance (Log
rank analysis p = 0.055) which is compelling given the small
numbers in the study and because the differences in rate of disease
progression between groups, and individuals within groups, are in
line with the differences revealed by the other measures of disease
burden. The study provides a rare opportunity to relate differential
gene expression patterns to different clinical outcomes to identify
profiles associated with improved outcome of infection that are
either naturally occurring (i.e. in unvaccinated animals) or induced
by BCG vaccination.
The microarray approach allowed simultaneous analysis of the
expression of tens of thousands of genes providing insights into all
aspects of the host response to BCG-vaccination and TB-
challenge. After BCG-vaccination, IFNG and IL2 genes were up-
regulated (Table 1), two cytokines which are vital for TB infection
control. Also up-regulated was the proinflammatory cytokine IL17,
which is produced by several cell types but is the primary cytokine
secreted by a subset of CD4+ T cells (Th17 cells), which are
important for vaccine-induced protection [23,24]. IL17-producing
T cells were generated in mice upon vaccination with a defined
subunit TB vaccine [11]. These cells preferentially trafficked
through or resided within the lungs, whereas a population of
IFNG-producing T cells that was also generated typically resided
within the central lymphoid tissue [11]. The position of these
IL17-producing memory T cells within the lungs meant they were
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able to respond quickly when stimulated by antigen and produce
IL17, leading to the recruitment of antigen-specific IFNG-
producing T cells from the central lymphoid tissue back to the
site of infection. This resulted in earlier cessation of bacterial
Figure 3. Expression of iron regulatory genes in PBMCs isolated from unvaccinated controllers and progressors at post-mortem.
Gene expression of a) ferritin heavy chain b) solute carrier family 11 member A1, and c) solute carrier family 11 member A2, d) transferrin receptor 1
and e) heme oxygenase 1 in unstimulated PBMCs isolated at post-mortem. The fold change from naı¨ve baseline levels was determined using RT-PCR.
To determine statistically significant differences of relative gene expression, a two-sample t-test was performed where * and ** represent P-values of
,0.05 and ,0.01, respectively. The data were from 3 animals. The symbol represents the median and the error bars represent the range.
doi:10.1371/journal.pone.0088149.g003
Host Response to BCG Vaccination and TB Challenge
PLOS ONE | www.plosone.org 7 February 2014 | Volume 9 | Issue 2 | e88149
growth and a reduced bacterial burden. The up-regulation of IL17
expression in the BCG-vaccinated cynomolgus macaques, which
controlled TB infection, supports a protective role for these cells.
Furthermore, the expression of IL17 post-vaccination has been
correlated with protection in a bovine model, in this case after
BCG and a viral vectored booster vaccine [24].
In addition to the up-regulation of IL17 post-vaccination in the
vaccinated controllers, several genes associated with the Th17
immune response were also up-regulated at six weeks post-
challenge in this group and also in the unvaccinated disease
controllers. This observation was not evident in cynomolgus
macaques that developed TB disease, further suggesting a
potential protective role for these genes. In particular, the genes
for IL17, IL21, IL22, IL23A, IL26, CCL20 and TNF, which are
either produced by, or required for the differentiation or
maintenance of Th17 cells, were all up-regulated in cynomolgus
vaccinated disease controllers. In addition, the expression of the
lineage-specific transcription factors, RORC and RORA, were also
significantly up-regulated in the cynomolgus vaccinated control-
lers. All these genes, with the exception of IL26 and RORC, were
also differentially expressed in the unvaccinated disease controllers
but only IL23A, CCL20 and TNF were up-regulated in the
Figure 4. Comparison of gene expression profiles generated from microarray and RT-PCR analysis. RT-PCR was used to validate
microarray expression data. The symbol represents the median and the error bars represent the range. Black triangles represent fold change in
expression from naı¨ve time-points as determined by microarray analysis; white triangles represent fold change in expression from naı¨ve time-points
as determined by RT-PCR analysis. * = differentially expressed (p,0.05).
doi:10.1371/journal.pone.0088149.g004
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cynomolgus disease progressors. Others have reported that Th17
cells and IL17 play an important role in the protective immune
response to TB [25–27] and also that suppression of the Th17
response may occur in patients with active TB [28,29]. Our
microarray analysis revealed no differential expression of Th17-
associated genes, including IL17 or IL22, in the PBMCs of the
cynomolgus macaques that developed active TB disease. This
observation may be explained by the movement of cells that
produce these cytokines out of the periphery and to the site of
infection where, in these animals, M. tuberculosis has been able to
establish an infection and, consequently, were able to suppress the
protective Th1 and Th17 responses. One possible cause of this
suppression could be an increase in levels of prostaglandin E2 in
the animals in which TB disease progressed, as indicated by
greater up-regulation of expression of genes involved in the
synthesis of PGE2, such as PTGS1, PTGS2 and PTGES, compared
to that seen in disease controllers. While at low concentrations
PGE2 can actually promote Th1 and Th17 cell differentiation
[30–32] and enhance IL17 production [33], at greater concen-
trations, PGE2 has been shown to inhibit Th1 differentiation and
T cell responses [34,35].
The up-regulation of IL17 at 6 weeks post-challenge was
observed in both vaccinated and unvaccinated disease controllers
with no significant difference in expression between the two
groups. This suggests that BCG-vaccination induces IL17 and a
protective immune response that can control subsequent infection,
as described above, but also some unvaccinated animals can
produce IL17 by the natural route of innate, then adaptive
immunity. As only one time-point was analysed post-challenge in
this study, the time it takes to raise this response was not
established. Therefore, it could be possible that vaccination results
in a stronger, faster induction of the response with an instant boost
to IL17 production, than that seen in the unvaccinated animals
able to control infection. This would need to be investigated
further.
A number of iron regulatory genes were differentially expressed
only in the disease progressors, including genes expressing the
heavy chain of ferritin, the divalent cation transporter, SLC11A1,
and the transferrin receptor, which is important in moving iron
bound to the extracellular iron storage protein, transferrin (TF),
into the cell. Iron is required by the host to raise an adequate
immune response as it is a cofactor for a number of metabolic
enzymes and in the generation of reactive oxygen species.
However, M. tuberculosis requires iron for its own metabolic
processes and successful growth. Upon infection, there is
competition between the host and bacteria over the iron in the
body. When a pathogen is encountered, a non-specific acute phase
response is induced within the host and iron is sequestered from
invading pathogens by reducing absorption of iron by the gut
(controlled by the protein, hepcidin) and by binding extracellular
iron to storage molecules, such as transferrin, lactoferrin and
ferritin. Mycobacteria deploy iron acquisition mechanisms to
combat this and produce two types of high affinity iron-chelating
siderophores; these are the cell-associated water-insoluble myco-
bactin and water-soluble carboxymycobactin, which is secreted
and able to remove iron bound to host proteins and transport it
back to the mycobacteria. In addition, a haem-degrading protein
has recently been identified in mycobacteria, suggesting these
bacteria can utilise free haem and haem from haemoglobin as an
iron source [36].
Three of the six unvaccinated cynomolgus macaques were
followed for a total of 28 weeks after M. tuberculosis challenge,
having controlled infection for the duration of the study. The
remaining three unvaccinated cynomolgus macaques reached
humane end-point criteria before the end of the study and were
euthanized. Their iron status was determined at post-mortem via
expression analysis of a range of iron regulatory genes. A clear
difference in expression of iron regulatory genes was observed with
a consistent and significant down-regulation of FTH1, SLC11A1,
SLC11A2, HMOX1 and TFRC in animals controlling the infection
(Figure 3). By reducing the storage protein ferritin, from which
mycobacteria can obtain iron via the action of their siderophores,
and reduction of the transferrin receptor, which would prevent
iron bound to transferrin from entering the cell, the host actively
restricts access of iron to the mycobacteria. At six weeks post-
challenge, IFNG was up-regulated in animals that controlled
infection. IFNG suppresses the expression of the transferrin
receptor on monocytes and also down-regulates the intracellular
concentration of ferritin [37,38]. The down-regulation of both
FTH1 and TFRC in these animals could, therefore, be a result of
the earlier actions of IFNG.
A role for iron in the control of TB disease has also been
observed in guinea pigs [39–41]; the ex vivo infection of splenocytes
isolated from protected BCG-vaccinated guinea pigs resulted in
down-regulation of iron regulatory genes including the ferritin
heavy chain and lactoferrin, and a heightened cytokine/IFNG
response, which is similar to the trend reported here.
In animals that were unable to control infection, an up-
regulation of IFNG was not observed at six weeks post-challenge;
consequently, the high iron-transferrin in the blood caused by the
acute phase response would result in the unidirectional and
coordinated up-regulation of TFRC and intracellular ferritin
content, and this was observed in samples taken at post-mortem
during end-stage disease. SLC11A1 was also up-regulated in the
unvaccinated disease progressors, as was SLC11A2, which
localizes with transferrin in the recycling endosomes of a number
of cell types and transports iron from the acidified lumen of the
endosomes into the cytoplasm [42]. The increase in expression of
genes involved in iron regulation seen in cynomolgus unvaccinated
disease progressors had the overall effect of increasing the
intracellular iron content which is available to the mycobacteria,
allowing it to thrive and establish a successful infection.
As discussed above, the Th1 and Th17 responses found to be
protective in the cynomolgus macaque model of TB in this study
have also been shown to be protective against TB in other studies
involving animals and also in humans [23–29]. However, the
neutrophil-driven interferon response identified in human TB
disease observed in the often cited study by Berry et al (2011) was
not observed. [43]. This is most likely due to the fact whole blood
was used to identify TB biomarkers in the Berry study whereas
PBMCs, a fraction of blood depleted of neutrophils, was utilised
here [43]. Nevertheless, despite this and other fundamental
differences in experimental set up, it has been reassuring to see
some genes appear across gene lists, highlighting the importance of
these genes in the response to tuberculosis infection. Comparison
of the 393-gene profile with differentially expressed genes in the
cynomolgus macaques that developed and succumbed to TB
disease revealed 61 genes in common, which is quite significant in
view of the considerable differences in design between the two
studies. Common genes included the immune-related genes
CD274, IL1RN, Fc fragment of IgA, receptor for (FCAR),
LILRA5, the interferon-inducible genes, CXCL10, GBP1 and
IFI44L and the toll-like receptors, TLR2 and TLR5 [43].
Conclusion
In conclusion, induction of a balanced Th1/Th17 response and
production of key effector cytokines, such as IFNG, IL2, IL17,
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IL21, IL22 and IL23A was observed in animals that controlled
infection, regardless of previous BCG-vaccination. The induction
of a protective Th1 and Th17 response is influenced by many
factors including the pro-inflammatory and inhibitory actions of
cytokines and metabolites. Changes that affect the delicate balance
between these factors could potentially sway the response in favour
of a protective Th1/Th17 response or alternatively toward
inhibition of these responses and, consequently, failure to control
infection. The ability to adequately restrict access to iron from the
mycobacteria is also an essential innate defence. The clear
differences between disease controllers and progressors suggest
that these responses could be used as indicators of protection or
disease.
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